<DOC>
	<DOCNO>NCT01175824</DOCNO>
	<brief_summary>The study comparison twice-daily insulin lispro low mixture versus once-daily basal insulin glargine once-daily prandial insulin lispro , participant Type 2 Diabetes .</brief_summary>
	<brief_title>Comparison Efficacy Safety Two Insulin Intensification Strategies</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Present type 2 diabetes mellitus Have take metformin and/or pioglitazone Have receive treatment basal insulin glargine , injected day , great equal 90 day Have glycosylated hemoglobin A1c ( HbA1c ) concentration great equal 7.5 % less equal 10.5 Have fast plasma glucose concentration less equal 6.7 millimoles per liter [ mmol/L , less equal 121 milligram per deciliter ( mg/dL ) ] , great 6.7 mmol/L ( great 121 mg/dL ) investigator considers titration basal insulin glargine possible safety reason Not pregnant breastfeed Have Type 1 Diabetes Their stable dose pioglitazone great maximum dose approve use combination insulin country Have body mass index ( BMI ) great 45 kilogram per square meter ( kg/m2 ) . Have history schedule mealtime ( prandial ) insulin use within 12 week screen visit total duration prandial insulin treatment great 2 week Have one episode severe hypoglycaemia within 24 week prior entry study Have cardiac disease functional status Class III IV Have history renal liver disease Have blood transfusion blood disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Glargine</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Insulin LISPRO</keyword>
	<keyword>Insulin</keyword>
</DOC>